| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00003246-199804000-00010 |
| P698 | PubMed publication ID | 9559600 |
| P2093 | author name string | Bollaert PE | |
| Larcan A | |||
| Levy B | |||
| Charpentier C | |||
| Audibert G | |||
| Debouverie M | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| hydrocortisone | Q26981430 | ||
| septic shock | Q1765564 | ||
| P304 | page(s) | 645-650 | |
| P577 | publication date | 1998-04-01 | |
| P1433 | published in | Critical Care Medicine | Q5186605 |
| P1476 | title | Reversal of late septic shock with supraphysiologic doses of hydrocortisone | |
| P478 | volume | 26 |
| Q35034145 | A Single-Center Review of Prescribing Trends and Outcomes of Corticosteroid Replacement Therapy in Critically Ill Children with Septic Shock |
| Q46417621 | A blueprint for a sepsis protocol |
| Q44316871 | A new role for glucocorticoids in septic shock: balancing the immune response |
| Q74294052 | A predictive model for mortality of bloodstream infections. Bedside analysis with the Weibull function |
| Q42751548 | Adjunct therapy for sepsis: how early? |
| Q33736253 | Adjunctive drug treatment in severe hypoxic respiratory failure. |
| Q79756568 | Adrenal axis function does not appear to be associated with hemodynamic improvement in septic shock patients systematically receiving glucocorticoid therapy |
| Q44503728 | Adrenal axis testing and corticosteroid replacement therapy in septic shock patients--local and national perspectives |
| Q39511421 | Adrenal dysfunction in hemodynamically unstable patients in the emergency department |
| Q35544715 | Adrenal function testing in patients with septic shock |
| Q37019710 | Adrenal insufficiency in critical illness |
| Q74396051 | Adrenal insufficiency in critically ill |
| Q43799463 | Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. |
| Q36787203 | Adrenal insufficiency in prolonged critical illness. |
| Q42254937 | Adrenal insufficiency in septic shock |
| Q43953574 | Adrenocortical function and multiple organ failure in severe sepsis |
| Q35732033 | Advances in sepsis therapy |
| Q64132601 | Advances in sepsis treatment |
| Q43416549 | Aldosterone secretion in patients with septic shock: a prospective study. |
| Q36910183 | An update on the diagnosis of adrenal insufficiency and the use of corticotherapy in critical illness |
| Q85716911 | Animal models of sepsis |
| Q34074976 | Anti-inflammatory therapies in sepsis and septic shock |
| Q33649871 | Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome |
| Q35206678 | Approach to intradialytic hypotension in intensive care unit patients with acute renal failure |
| Q45190396 | Arginine-vasopressin and corticosteroids in septic shock: engaged but not yet married! |
| Q46792531 | Association between adrenal insufficiency and ventilator weaning |
| Q90695562 | Association of Corticosteroid Treatment With Outcomes in Adult Patients With Sepsis: A Systematic Review and Meta-analysis |
| Q34285366 | Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia |
| Q42969992 | Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism |
| Q41827105 | CORTICUS: the end of unconditional love for steroid use? |
| Q36059231 | Can 1 microg of cosyntropin be used to evaluate adrenal insufficiency in critically ill patients? |
| Q37901552 | Clinical approach to adrenal insufficiency in hospitalised patients |
| Q35686356 | Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. |
| Q24805270 | Clinical review: corticotherapy in sepsis |
| Q34577529 | Clinical trials of immunomodulatory therapies in severe sepsis and septic shock |
| Q90419415 | Closed-loop vasopressor control: in-silico study of robustness against pharmacodynamic variability |
| Q44572485 | Comparative effects of dexamethasone and L-canavanine in experimental septic shock |
| Q28367341 | Congenital adrenal hyperplasia: management during critical illness |
| Q41760154 | Corticosteroid administration is associated with improved outcome of patients presenting high inflammatory cytokine levels during septic shock |
| Q90666843 | Corticosteroids for Septic Shock: Another Chapter in the Saga |
| Q24562848 | Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis |
| Q39387531 | Corticosteroids for severe sepsis: an evidence-based guide for physicians |
| Q24187207 | Corticosteroids for treating sepsis |
| Q34575310 | Corticosteroids in ARDS. An evidence-based review |
| Q39408165 | Corticosteroids in sepsis: an updated systematic review and meta-analysis (protocol). |
| Q40449925 | Corticosteroids in septic shock: What should the decision in pediatrics be? |
| Q37727023 | Corticosteroids in septic shock: a systematic review and network meta-analysis. |
| Q93555004 | Corticosteroids reduce inotrope requirements in hypotensive liver failure |
| Q46694073 | Cortisol changes among patients with septic shock and the relationship to ICU and hospital stay |
| Q42523779 | Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis |
| Q44695296 | Cortisol levels and mortality in severe sepsis. |
| Q24798383 | Cortisol replacement for severe sepsis and septic shock: what should I do? |
| Q44731038 | Cortisone substitution in sepsis. Is less more? |
| Q40541106 | Cosyntropin as a diagnostic agent in the screening of patients for adrenocortical insufficiency |
| Q35622664 | Critical issues in endocrinology |
| Q51496003 | Critical-care studies: redefining the rules. |
| Q56798101 | Current perspectives for the use of corticosteroids in sepsis: patient selection is the key |
| Q33642584 | Current therapy for sepsis |
| Q36191631 | Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia |
| Q36982683 | Diagnosis and treatment of adrenal insufficiency in the critically ill patient |
| Q37924623 | Diagnosis of adrenal failure in critically ill patients. |
| Q78213128 | Diagnosis of relative adrenal insufficiency in critically ill patients |
| Q91977468 | Diastolic shock index and clinical outcomes in patients with septic shock |
| Q34004035 | Differential host inflammatory responses to viable versus antibiotic-killed bacteria in experimental microbial sepsis |
| Q79886650 | Discordant response to ACTH stimulation in patients with septic shock |
| Q89133430 | Do low-dose corticosteroids improve survival or shock reversal from septic shock in adults? Meta-analysis with trial sequential analysis |
| Q77983574 | Early activation of hepatic NFkappaB and NF-IL6 in polymicrobial sepsis correlates with bacteremia, cytokine expression, and mortality |
| Q36295952 | Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity |
| Q36093460 | Early initiation of low-dose corticosteroid therapy in the management of septic shock: a retrospective observational study |
| Q40354685 | Economic evaluation in critical care: a focus on severe sepsis in oncology. |
| Q36670553 | Effect of early goal-directed therapy on mortality in patients with severe sepsis or septic shock: a meta-analysis of randomised controlled trials |
| Q44391665 | Effect of glucocorticoid pretreatment on oxidative liver injury and survival in jaundiced rats with endotoxin cholangitis |
| Q58703880 | Effect of high-volume hemofiltration on mortality in critically ill patients: A PRISMA-compliant systematic review and meta-analysis |
| Q41789482 | Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial |
| Q44613105 | Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock |
| Q55293606 | Effects of Hydrocortisone on Regulating Inflammation, Hemodynamic Stability, and Preventing Shock in Severe Sepsis Patients. |
| Q46960834 | Effects of hydrocortisone stress-dose therapy in septic shock (part I): influence on hemodynamic stability and plasma nitrite/nitrate levels |
| Q28362956 | Effects of methylprednisolone on intracellular bacterial growth |
| Q37147247 | Effects of pentoxifylline on TNF-alpha and lung histopathology in HCL-induced lung injury |
| Q48676741 | Effects of single dose of dexamethasone on patients with systemic inflammatory response |
| Q34554713 | Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery |
| Q37343546 | Endocrinal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease |
| Q34761359 | Endocrine and metabolic issues in the management of the chronically critically ill patient |
| Q35151400 | Endocrine evaluation of patients with critical illness |
| Q35093114 | Endogenous versus exogenous glucocorticoid responses to experimental bacterial sepsis |
| Q34837530 | Endotoxin antagonism: conceptual basis and therapeutic potential |
| Q34449865 | Eritoran: the evidence of its therapeutic potential in sepsis |
| Q28262634 | Etomidate for emergency anaesthesia; mad, bad and dangerous to know? |
| Q43951992 | Etomidate, adrenal dysfunction and critical care |
| Q64133116 | Evidence of altered cortisol metabolism in critically ill patients: a prospective study |
| Q34481636 | Experimental and emerging therapies for sepsis and septic shock |
| Q40294910 | Fever control using external cooling in septic shock: a randomized controlled trial |
| Q44185696 | Glucocorticoids aggravate hyperoxia-induced lung injury through decreased nuclear factor-kappa B activity |
| Q34175968 | Glucocorticoids as an emerging pharmacologic agent for cardiopulmonary resuscitation |
| Q37398445 | Glucocorticosteroid in treatment of severe pneumonia |
| Q30655904 | Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis |
| Q33288475 | Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature |
| Q43784073 | Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy |
| Q58100521 | Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions |
| Q92685325 | Hydrocortisone Reduces 28-day Mortality in Septic Patients: A Systemic Review and Meta-analysis |
| Q43511886 | Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics? |
| Q44615860 | Hydrocortisone improved haemodynamics and fluid requirement in surviving but not non-surviving of severely burned patients |
| Q55710423 | Hydrocortisone in septic shock: all the questions answered? |
| Q45158566 | Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study |
| Q45800675 | Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia. |
| Q44613359 | Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure |
| Q46566543 | Hypothalamic-pituitary-adrenal axis and septic shock |
| Q34627670 | Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia |
| Q32060206 | Hypothalamic-pituitary-adrenal insufficiency |
| Q46214441 | Immediate hemodynamic response to steroid treatment in septic shock |
| Q34547881 | Immunotherapy of sepsis |
| Q90680354 | Impact and Beneficial Critical Points of Clinical Outcome in Corticosteroid Management of Adult Patients With Sepsis: Meta-Analysis and GRADE Assessment |
| Q35802761 | Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve |
| Q35064976 | Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis |
| Q24200934 | Interventions for preventing critical illness polyneuropathy and critical illness myopathy |
| Q24241368 | Interventions for preventing critical illness polyneuropathy and critical illness myopathy |
| Q24243431 | Interventions for preventing critical illness polyneuropathy and critical illness myopathy |
| Q46609035 | Is hydrocortisone an effective treatment for septic shock? |
| Q34463493 | Is nitric oxide overproduction the target of choice for the management of septic shock? |
| Q57571675 | Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis |
| Q34403869 | Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. |
| Q37829657 | Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies |
| Q91909204 | L’usage des corticoïdes en réanimation |
| Q37805910 | Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. |
| Q38450665 | Management of severe sepsis: advances, challenges, and current status |
| Q34745963 | Management of the acute respiratory distress syndrome. |
| Q36413778 | Managing stress in critical illness: a question of balance |
| Q24802854 | Measurements of serum free cortisol in critically ill patients |
| Q74210483 | Microvascular responses to sepsis: clinical significance |
| Q46331188 | Modulation of glucocorticoid receptor expression, inflammation, and cell apoptosis in septic guinea pig lungs using methylprednisolone |
| Q34624165 | Multi-organ renal failure in the elderly |
| Q44044861 | New approaches to intensive care for sepsis |
| Q35622651 | New approaches to the treatment of sepsis |
| Q33840119 | New rationale for glucocorticoid treatment in septic shock |
| Q34481640 | New therapies and vaccines for meningococcal disease |
| Q38131458 | Noncanonical Nuclear Factor Kappa B (NF-κB) Signaling and Potential for Therapeutics in Sepsis |
| Q37367885 | Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response |
| Q44591511 | Nuclear factor-κB: Is it a therapeutic target for the adjuvant treatment of sepsis? * |
| Q34576365 | Optimal management of septic shock. Rapid recognition and institution of therapy are crucial |
| Q43794530 | Organ dysfunction during sepsis |
| Q30543305 | Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations |
| Q38141738 | Pathophysiologic mechanisms in septic shock |
| Q35779090 | Pediatric acute hypoxemic respiratory failure: management of oxygenation |
| Q37200292 | Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations |
| Q30318070 | Perioperative Addisonian crisis |
| Q33893308 | Pharmacologic issues in the management of septic shock |
| Q21195121 | Physiological-dose steroid therapy in sepsis [ISRCTN36253388] |
| Q34999481 | Pro-con debate: steroid use in ACTH non-responsive septic shock patients with high baseline cortisol levels |
| Q24796470 | Pro/con clinical debate: are steroids useful in the management of patients with septic shock? |
| Q46444385 | Prognostic value of relative adrenal insufficiency after out-of-hospital cardiac arrest |
| Q37710052 | Protective effects of the combination of sodium ferulate and oxymatrine on cecal ligation and puncture-induced sepsis in mice |
| Q35056046 | Recent developments in the treatment of sepsis |
| Q24798436 | Recently published papers: topical issues in pharmacology |
| Q28195791 | Reducing mortality in sepsis: new directions |
| Q91692986 | Reevaluating the Role of Corticosteroids in Septic Shock: An Updated Meta-Analysis of Randomized Controlled Trials |
| Q36273664 | Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis |
| Q64964540 | Relative Adrenal Insufficiency in Pediatric Septic Shock. |
| Q37590213 | Revisiting steroid treatment for septic shock: molecular actions and clinical effects--a review |
| Q46907862 | Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis |
| Q35670040 | Role of corticosteroids in septic shock |
| Q35925664 | Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis |
| Q35497326 | Salivary cortisol can replace free serum cortisol measurements in patients with septic shock |
| Q78772835 | Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q34285308 | Septic shock |
| Q47152131 | Serum Cortisol Level in Indian Patients with Severe Sepsis/Septic Shock. |
| Q37562996 | Severe sepsis and septic shock: management and performance improvement. |
| Q40832794 | Should all adjunctive corticosteroid therapy be avoided in the management of hemodynamically stabile Staphylococcus aureus bacteremia? |
| Q24813320 | Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated). |
| Q43570891 | Steroids and Drotrecogin Alfa (Activated) for Severe Sepsis |
| Q39781169 | Steroids in sepsis: another swing of the pendulum in our clinical trials |
| Q44573138 | Stress of dying is not suppressed by high-dose morphine or by dementia |
| Q34834695 | Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults |
| Q34162321 | Stress-induced hormonal alterations |
| Q33642523 | Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis |
| Q35128911 | Such stuff as dreams are made on: mediator-directed therapy in sepsis |
| Q35966961 | Surgical sepsis: dysregulation of immune function and therapeutic implications. |
| Q64126988 | Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock |
| Q38433744 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. |
| Q29615429 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 |
| Q24644984 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 |
| Q37585835 | Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress |
| Q22306309 | Systemic Steroids in Severe Sepsis and Septic Shock |
| Q79429276 | The ACTH test should not be used in the decision to start low dose steroids in catecholamine-dependent septic shock |
| Q95283432 | The Efficacy, Safety, and Optimal Regimen of Corticosteroids in Sepsis: A Bayesian Network Meta-Analysis |
| Q24797091 | The International Sepsis Forum's controversies in sepsis: corticosteroids should be used to treat septic shock |
| Q24796989 | The International Sepsis Forum's controversies in sepsis: corticosteroids should not be routinely used to treat septic shock |
| Q87791624 | The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016) |
| Q50052469 | The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). |
| Q35107094 | The Japanese guidelines for the management of sepsis |
| Q50761738 | The Treatment of Severe Group A Streptococcal Infections. |
| Q44253267 | The adrenal response after severe trauma |
| Q34807379 | The altered adrenal axis and treatment with glucocorticoids during critical illness |
| Q42962083 | The diagnosis of adrenal insufficiency in the critically ill patient: does it really matter? |
| Q44448695 | The effect of methylprednisolone on treatment in rats with induced sepsis |
| Q43602418 | The effect of short-term prophylactic methylprednisolone on the incidence and severity of postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopulmonary bypass |
| Q43828893 | The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors |
| Q42321768 | The effects of moderate-dose steroid therapy in sepsis: A placebo-controlled, randomized study. |
| Q36060153 | The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis |
| Q44373855 | The effects of supraphysiological doses of corticosteroids in hypotensive liver failure |
| Q35101483 | The hypothalamic-pituitary-adrenal axis and low-dose glucocorticoids in the treatment of septic shock |
| Q81525465 | The hypothalamic-pituitary-adrenal axis in critical illness |
| Q37189110 | The role of corticosteroids in severe community-acquired pneumonia: a systematic review |
| Q35055006 | The use of corticosteroids in severe sepsis and acute respiratory distress syndrome |
| Q36097257 | The use of steroids in children with septicemia: review of the literature and assessment of current practice in PICUs in the UK. |
| Q78428597 | Thyroid storm presenting with no fever and an absolute adrenal insufficiency |
| Q38949018 | Timing, method and discontinuation of hydrocortisone administration for septic shock patients |
| Q35055011 | Treatment of impaired perfusion in septic shock |
| Q36676253 | Treatment of sepsis: current status of clinical immunotherapy. |
| Q44804215 | Treatment of severe sepsis and septic shock |
| Q36744024 | Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa |
| Q36505487 | Treatment options for severe sepsis and septic shock |
| Q27008289 | Update on adrenal insufficiency in patients with liver cirrhosis |
| Q34153235 | Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. |
| Q28078523 | Urosepsis--Etiology, Diagnosis, and Treatment |
| Q43262439 | Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei. |
| Q36399253 | Using the high-dose corticotropin test to diagnose relative adrenal insufficiency in vasopressor-dependent septic shock. |
| Q44564363 | Weapons of pressure resuscitation for septic shock |
| Q79285415 | Which therapeutic prospects in the septic syndrome? |
| Q33338424 | Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis |
| Q83340506 | [Corticosteroid insufficiency in the critically ill. Pathomechanisms and recommendations for diagnosis and treatment] |
| Q81888444 | [Management of severe sepsis and septic shock in 2005--a practical approach] |
Search more.